NCT06122714 - A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

December 4, 2024

Study Completion Date

December 4, 2024

Conditions

Healthy Participants

Interventions

DRUG

AZD4144 Part A

Part A: Participants will be administered a single oral dose on Day 1.

DRUG

AZD4144 Part B

Part B: Participants will be administered a single dose on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.

DRUG

Placebo Part A

Part A: Participants will be administered a single oral dose of matching placebo on Day 1.

DRUG

Placebo Part B

Part B: Participants will be administered a single dose of matching placebo on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.

Trial Locations (2)

21225

Research Site, Brooklyn

91206

Research Site, Glendale